 All patients will receive daily perifosine qhs with food. In the initial phase I study, 3 patients will be entered into a specified combination of perifosine and bortezomib cohorts. If no dose-limiting toxicity is observed, then three additional patients will be entered in cohort 4 - a full dose of bortezomib 1.3 mgm2 on days 1, 4, 8 and 11 every 3 weeks. If this dose is tolerated it will be used for the phase II study, otherwise an intermediate dose of 1 mgm2 on days 1, 4, 8, and 11 every 3 weeks will be employed. 